Business
Guardant Health Reports Third Quarter 2025 Financial Results and Increases 2025 Revenue Guidance
Revenue growth of 39% broadly driven by strong performance across Oncology, Screening, and Biopharma & Data Raises 2025 revenue guidance to $965 to $970
About this update from Guardant Health, Inc.
[{"type":"text","content":"\nRevenue growth of 39% broadly driven by strong performance across Oncology, Screening, and Biopharma & Data\n\n\nRaises 2025 revenue guidance to $965 to $970 million, representing year-over-year growth of 31%\n\n\n PALO ALTO, Calif.--(BUSINESS WIRE)--\nGuardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended September 30, 2025.\n\n\nThird Quarter 2025 Financial Highlights\n\n\nFor the three-month period ended September 30, 2025, as compared to the same period of 2024:\n\n\n\nReported total revenue of $265.2 million, an increase of 39%, driven by:\n\n\n\n\nOncology revenue of $184.4 million, an increase of 31%, and approximately 74,000 oncology tests, an increase of 40%\n\n\n\nScreening revenue of $24.1 million, and approximately 24,000 Shield screening tests, compared to $1.0 million in the prior year period\n\n\n\nBiopharma & Data revenue of $54.7 million, an increase of 18%\n\n\n\n\nGenerated non-GAAP gross margin of 66%, compared to 63% in the third quarter of 2024\n\n\n\nRecent Operating Highlights\n\n\n\nExpanded Shield to include multi-cancer detection (MCD) and initiated a large-scale real-world data initiative for Shield MCD\n\n\n\nAnnounced strong real-world performance data for Shield MCD utilizing the InfinityAI learning engine\n\n\n\nEstablished strategic collaborations with Quest Diagnostics and PathGroup to further accelerate nationwide access to Shield\n\n\n\nImproved stage I performance in Shield V2 CRC screening test\n\n\n\nEstablished a partnership with American Cancer Society to expand cancer screening access and advance health equity\n\n\n\nReached a major milestone with the submission of Guardant360 Liquid PMA application to FDA\n\n\n\nSubmitted Reveal immuno-oncology monitoring data package to MolDx for Medicare reimbursement\n\n\n\nReceived new Guardant360 companion diagnostic approvals for breast cancer and non-small cell lung cancer\n\n\n\n“This was an exceptional quarter for Guardant with broad-based growth across our business,” said Helmy Eltoukhy, co-founder and co-CEO. “Oncology volumes grew 40% year-over-year, driven by very strong performance across all products, including the fifth consecutive quarter of accelerating Guardant360 Liquid volume growth. Notably, this quarter we crossed over $1 billion in annualized revenue. Thi...